Evidence map›Paper›PMID 39658949›Full record

ArticleInternational journal of laboratory hematology2025

A New Diagnostic Approach for Myelodysplastic Neoplasms Using a Combination of Scores Based on Flow Cytometry and Automated Hematology Sysmex XN Analyzers.

Ludovic Firrera, Benjamin Podvin, Julien Herlem, Marion Magierowicz, Alexandre Willaume, Vincent Thibaud, Agnès Charpentier

Abstract read
In one paragraph

Article in International journal of laboratory hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ludovic FirreraLaboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France.ORCID https://orcid.org/0009-0003-8491-2532
Benjamin PodvinLaboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France.
Julien HerlemLaboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France.
Marion MagierowiczLaboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France.
Alexandre WillaumeHematology Department, Hospital Group of Lille Catholic University, Lille, France.
Vincent ThibaudHematology Department, Hospital Group of Lille Catholic University, Lille, France.
Agnès CharpentierLaboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe first-step in diagnosis of myelodysplastic neoplasms (MDS) is essentially based on bone marrow cytomorphology. However, cytomorphology of MDS is often a difficult exercise, subject to inter-operator variability. Our study aims to evaluate whether the combination of two dysplasia scores, the extended Ogata score and the MDS-CBC score, could improve the screening of MDS patients among patients with chronic cytopenia.

methodsExtended Ogata score and MDS-CBC score have been measured on a retrospective cohort of 63 patients with a clinical suspicion of MDS based on the presence of cytopenia. Among these patients, 33 patients were diagnosed as MDS (MDS group) and 30 patients were diagnosed with another cause of cytopenia (non-MDS cytopenic control group).

resultsOur results show excellent performance of the combined scores in predicting MDS when the two scores are concordant: positive predictive value (PPV) = 96% and negative predictive value (NPV) = 92%. In comparison, in the same cohort, extended Ogata score alone showed a PPV = 90% and NPV = 79%, MDS-CBC score alone showed a PPV = 85% and NPV = 86%.

conclusionFor the first time, our results show that the combination of these two dysplasia scores constitutes a useful and rapid tool for the assessment of dysplasia associated with MDS. In the MDS diagnostic process, the use of combined scores could constitute a valuable tool to enable early strong prediction of MDS in cytopenic patients and to target patients who initially require additional genetic assays.

Indexed as

Flow CytometryMyelodysplastic SyndromesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studiesdiagnosisextended OgataMDS‐CBCmyelodysplastic neoplasmsscoreSysmex

Identifiers

PMID39658949
PMCPMC11885685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.